We are live on
!
Find out more
TC
Tavio Capital Portfolio holdings
AUM
$75.4M
1-Year Est. Return
27.99%
This Fund
S&P 500
This Quarter
Est. Return
+9.83%
1 Year Est. Return
+27.99%
3 Year Est. Return
+81.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$295M
AUM Growth
+$83.2M
(+39%)
Cap. Flow
+$60.6M
Cap. Flow
% of AUM
20.53%
Top 10 Holdings %
Top 10 Hldgs %
80.23%
Holding
20
New
8
Increased
3
Reduced
5
Closed
3
Top Buys
| 1 |
Quest Diagnostics
DGX
|
+$37.8M |
| 2 |
Cencora
COR
|
+$28.7M |
| 3 |
Centene
CNC
|
+$19.4M |
| 4 |
CELG
Celgene Corp
CELG
|
+$10.4M |
| 5 |
UnitedHealth
UNH
|
+$10.2M |
Top Sells
| 1 |
Molina Healthcare
MOH
|
+$19.7M |
| 2 |
Cardinal Health
CAH
|
+$15.1M |
| 3 |
DaVita
DVA
|
+$14.1M |
| 4 |
Universal Health Services
UHS
|
+$13.3M |
| 5 |
Boston Scientific
BSX
|
+$8.45M |
Sector Composition
| 1 | Healthcare | 96.56% |
| 2 | Financials | 3.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Quest Diagnostics
DGX
$23.3B
| $39.9M | 13.5% |
+362,612
| New | +$37.8M |
|
2
Elevance Health
ELV
$80.9B
| $39.2M | 13.26% |
164,532
-13,281
| -7% | -$3.08M |
|
|
3
Cencora
COR
$59.9B
| $27.9M | 9.44% |
+327,089
| New | +$28.7M |
|
4
CVS Health
CVS
$137B
| $27.7M | 9.37% |
430,000
+34,760
| +9% | +$2.29M |
|
|
5
Centene
CNC
$32.8B
| $20.8M | 7.03% |
+337,192
| New | +$19.4M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
| $20.5M | 6.93% |
164,933
+46,244
| +39% | +$5.4M |
|
7
HCA Healthcare
HCA
$82.3B
| $20.2M | 6.86% |
197,318
+67,385
| +52% | +$6.82M |
|
8
Humana
HUM
$48B
| $15.8M | 5.37% |
53,232
-12,265
| -19% | -$3.59M |
|
|
9
Boston Scientific
BSX
$65.4B
| $14.2M | 4.82% |
435,330
-280,164
| -39% | -$8.45M |
|
10
Heron Therapeutics
HRTX
$89.1M
| $10.8M | 3.64% |
276,729
-75,000
| -21% | -$2.39M |
|
|
11
UnitedHealth
UNH
$387B
| $10.4M | 3.53% |
+42,435
| New | +$10.2M |
|
|
AET
12
DELISTED
Aetna Inc
AET
| $10.2M | 3.44% |
+55,346
| New | +$9.86M |
|
|
13
Molina Healthcare
MOH
$11.7B
| $10M | 3.39% |
102,238
-226,034
| -69% | -$19.7M |
|
|
CELG
14
DELISTED
Celgene Corp
CELG
| $9.96M | 3.37% |
+125,408
| New | +$10.4M |
|
15
Travere Therapeutics
TVTX
$5.27B
| $8.01M | 2.71% |
293,923
| – | – |
|
|
FOLD
16
DELISTED
Amicus Therapeutics
FOLD
| $6.29M | 2.13% |
+402,955
| New | +$6.09M |
|
|
ZGNX
17
DELISTED
Zogenix, Inc.
ZGNX
| $3.54M | 1.2% |
+80,160
| New | +$3.3M |
|
|
18
Cardinal Health
CAH
$53.5B
| – | – |
-241,546
| Closed | -$15.1M |
|
|
19
DaVita
DVA
$15.2B
| – | – |
-213,772
| Closed | -$14.1M |
|
|
20
Universal Health Services
UHS
$9.15B
| – | – |
-111,967
| Closed | -$13.3M |
|
Similar funds
PC
EGPO
AIS
MCMT
NBG
FC
SCM
MVM
Tavio Capital's Q2 2018 Portfolio in Review
As of Q2 2018, Tavio Capital held 20 positions worth $295M, up 39% from $212M the previous quarter. Its ten largest holdings account for 80% of the portfolio.
Tavio Capital deployed $60.6M of net new capital in Q2 2018, opening 8 new positions and adding to 3 existing holdings. Its largest new stake was Quest Diagnostics: 362,612 shares worth $39.9M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 100% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Molina Healthcare, an estimated $19.7M trimmed.
- Tavio Capital's largest Q2 2018 buy was Quest Diagnostics: 362,612 shares worth $39.9M.
- Tavio Capital added most to HCA Healthcare in Q2 2018, an estimated $6.82M increase.
- Tavio Capital's biggest Q2 2018 reduction was Molina Healthcare, cutting an estimated $19.7M.
- Tavio Capital fully exited Cardinal Health in Q2 2018, selling an estimated $15.1M.
- Tavio Capital's ten largest holdings make up 80% of its $295M portfolio in Q2 2018.
- Tavio Capital opened 8 new positions and closed 3 in Q2 2018.
- Tavio Capital's portfolio value rose 39% quarter-over-quarter to $295M.
Based on Tavio Capital's 13F filing for Q2 2018, filed 13 Aug 2018.